Beckman coulter diagnostics launches industry first fully automated, high throughput bd-tau research use only immunoassay test, advancing neurodegenerative clinical research

Beckman coulter also announces development of ass-42 research use only immunoassay test brea, calif. , sept. 10, 2025 /prnewswire/ -- beckman coulter diagnostics, a danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated brain-derived tau (bd-tau) research use only (ruo) immunoassay test.
DHR Ratings Summary
DHR Quant Ranking